LIVE
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%

Aurobindo Pharma Gains on Lannett Deal, Bajaj Finance Raises ₹1,455 Cr

By SivamAurobindo Pharma Gains on Lannett Deal, Bajaj Finance Raises ₹1,455 Cr

Aurobindo Pharma shares surge on US FTC approval for Lannett acquisition. Bajaj Finance raises ₹1,455 crore via NCDs, boosting its financials.

Aurobindo Pharma Rises on US FTC Nod for Lannett Deal

Aurobindo Pharma’s shares jumped by 1.96% to Rs 1471.40 after its arm secured the US Federal Trade Commission’s (FTC) approval.

This approval is for acquiring 100% membership interest in Lannett, a strategic move set to bolster Aurobindo’s presence in the U.S. generics market. The deal also offers diversification into a specialized, high-value therapeutic category.

  • The stock opened at Rs 1461.95 and touched a high of Rs 1480.00.
  • A total of 109274 shares were traded.
  • The company has a current market cap of Rs 84658.23 crore.

Bajaj Finance Secures
₹1,455 Crore via NCDs

In other corporate news, Bajaj Finance moved up by 0.55% to Rs 964.40.

This gain followed its Debenture Allotment Committee’s approval to raise Rs 1,455.40 crore through Non-Convertible Debentures (NCDs) on June 18, 2026.

  • The scrip opened at Rs 951.65 and traded with a high of Rs 971.10.
  • A total of 304675 shares were traded.
Home/business/Article